search
Back to results

Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL

Primary Purpose

B-ALL

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
ThisCART19A
Sponsored by
Zhejiang University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for B-ALL

Eligibility Criteria

18 Years - 64 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. All subjects or legal representatives must sign a voluntary letter of consent approved by the IRB in person prior to the commencement of any screening procedure;
  2. Patients diagnosed with B-ALL according to the Chinese Guidelines for the Diagnosis and Treatment of Adult Acute Lymphoblastic Leukemia (2021 edition);
  3. There is no gender limitation, age 18-65 (upper limit not included);
  4. Consistent with the diagnosis of recurrent refractory B-ALL. Recurrence: was defined as the recurrence of lymphoblasts(≥5%) in peripheral blood or bone marrow or extramedullary diseasefor patients who had acquired CR ; Refractory :was defined as failure to CR or CRi at the end of induction therapy (generally referred to 4-week regimen or Hyper-CVAD regimen);Patients with Ph+ R/R ALL who failed after 2-line TKI treatment, were intolerant to TKI treatment or were not suitable for TKI treatment;

    The following factors can coexist:

    A) Failure to prepare autologous CAR-T (definition: too few autologous lymphocytes [200/ML] or cannot meet the release standard); B) Experienced treatment with auto car-T/berintoomumab/ CD22 antibody conjugation drugs; C) ≥100 days after hematopoietic stem cell transplantation; D) high-risk patients (High risk was defined as a high white blood cell count ≥30×109/L at diagnosis or with poor cytogenetic prognosis);

    • Hypodiploid (<44 chromosomes);
    • KMT2A rearrangement: t (4;11) or otherwise;
    • t (v;q32)/IgH;
    • t (9;22) (q34;q11.2) or BCR-ABL1;
    • Complex karyotype (≥5 chromosomal abnormalities);
    • BCR-ABL1-like (Ph-like) ALL;

      • JAK-STAT (CRLF2r, EPORr, JAK1/2/3r, TYK2r, mutations of SH2B3, IL7r, Jak1/2/3 );
      • ABL class( rearrangement of ABL1, ABL2, PDGFRA, PDGFRB, FGFR);
      • Other (NTRKr, FLT3r, LYNr, PTK2Br);
    • Intrachromosomal amplification of chromosome 21 (IAMP21-ALL);
    • t (17;19) : TCF3-HLF fusion ;
    • Alterations of IKZF1; E) Extramedullary lesions.
  5. The expected survival time is ≥12 weeks;
  6. ECOG score 0-1;
  7. Had good organic function during screening
  8. CD19 was still expressed in leukemia cells in bone marrow, peripheral blood or biopsy tissue by flow cytometry within one month prior to informed consent (after the last treatment).

Exclusion Criteria:

  1. Allergic to preconditioning measures.
  2. Patients with other malignancies other than B-cell malignancies within 5 years prior to screening. Patients with cured skin squamous carcinoma,basal carcinoma, non-primary invasive bladder cancer, localized low-risk prostate cancer, in situ cervical/breast cancer can be recruited.
  3. Uncontrollable bacterial, fungal and viral infection during screening.
  4. Patients had pulmonary embolism within 3 months prior to enrollment.
  5. Had intolerant severe cardiovascular and cerebrovascular diseases and hereditary diseases prior to enrollment.
  6. Imaging confirmed the presence of central nervous system involvement (both primary and secondary) and obvious symptoms at the time of screening.
  7. Active HBV or HCV or HIV or Syphilis infection. HBV-DNA < 2000 IU/mL can be enrolled, but should admitted to use anti-virus drugs such as entecavir, tenufovir, etc, and supervisory the relative indication during the treatment.
  8. Combined systemic steroid use (e.g., prednisone ≥20mg) within 3 days prior to screening. Or systemic diseases that require long-term use of immunization Inhibitor.
  9. Vaccinated with influenza vaccine within 2 weeks prior to cleansing (SARS-COV19 can be included, inactivated, live/non-live adjuvant vaccinations allowed to be included) .
  10. Patients who are receiving GvHD treatment; Patients without GvHD and who had stopped immunosuppressive drugs for at least 1 month were eligible for inclusion.
  11. Women who are in pregnant or lactating, and female subjects or partners who plan to be pregnant within 1 year after cell infusion. Male subjects who plan pregnancy within 1 year after infusion.
  12. Any ineligibility conditions considered by the investigator that may increase the risk of the subject or interfere with the results of the study;

Sites / Locations

  • The First Hospital of Zhejiang Medical Colleage Zhejiang UniversityRecruiting
  • The first affiliated hospital of medical college of zhejiang universityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

ThisCART19A 5×10^6 cells/kg for dose level 1

ThisCART19A 8×10^6 cells/kg as dose level 2

ThisCART19A 12×10^6 cells/kg as dose level 3

Arm Description

Patients will receive 5×10^6 cells/kg of ThisCART19A

Patients will receive 8×10^6 cells/kg of ThisCART19A

Patients will receive 12×10^6 cells/kg of ThisCART19A

Outcomes

Primary Outcome Measures

Dose limited toxicity(DLT) observation and the incidence of treatment-emergent adverse events(TEAE) which more than or equal to grade 3 in each dose level
DLT is defined as the incidence of severe adverse events related to ThisCART19A more than 33% in each dose level.
The incidence of all grade TEAEs and ≥3 grade TEAEs
Incidence of treatment-emergent adverse events (TEAEs) and ≥3 grade TEAEs

Secondary Outcome Measures

Objective response rate
Objective response rate (ORR = CR + CRi) of ThisCART19A within 3 months after administration
The change characteristics of chimeric antigen receptor(CAR)-T cell number and copy number in patients after infusion
Track CAR-T cells expansion in patients after infusion by flow cytometry and qPCR
Changes in cytokine level after ThisCART19A infusion.
Calculate the change of cytokine level in peripheral blood by flow cytometry after ThisCART19A infusion. Cytokines include IL-1β、IL-2、IL-4、IL-6、IL-8、IL-10、IL-12、IL-17、TNF-α、IFN-γ、TGF-β.
Changes in immune effect cells count after ThisCART19A infusion.
Calculate the change of immune effect cells count in peripheral blood by flow cytometry after ThisCART19A infusion. Immune effect cells include T cell, B cell, NK cell.
MRD response rate
Percentage of participants with minimal residual disease (MRD) response in patients with CR (complete response) and CRi (CR with incomplete blood count recovery) ; MRD Response is defined as leukemic cells in bone marrow <0.01% by flow cytometry (sensitivity at least 0.001%)

Full Information

First Posted
April 9, 2022
Last Updated
April 26, 2022
Sponsor
Zhejiang University
search

1. Study Identification

Unique Protocol Identification Number
NCT05350787
Brief Title
Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL
Official Title
To Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Relapsed and Refractory Acute B-cell Leukemia
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Recruiting
Study Start Date
March 18, 2022 (Actual)
Primary Completion Date
March 30, 2024 (Anticipated)
Study Completion Date
April 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Zhejiang University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This is an open label, phase I study to assess the safety, efficacy and pharmacokinetics of ThisCART19A in patients with relapsed and refractory acute B-cell leukemia

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
B-ALL

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
16 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ThisCART19A 5×10^6 cells/kg for dose level 1
Arm Type
Experimental
Arm Description
Patients will receive 5×10^6 cells/kg of ThisCART19A
Arm Title
ThisCART19A 8×10^6 cells/kg as dose level 2
Arm Type
Experimental
Arm Description
Patients will receive 8×10^6 cells/kg of ThisCART19A
Arm Title
ThisCART19A 12×10^6 cells/kg as dose level 3
Arm Type
Experimental
Arm Description
Patients will receive 12×10^6 cells/kg of ThisCART19A
Intervention Type
Biological
Intervention Name(s)
ThisCART19A
Intervention Description
ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
Primary Outcome Measure Information:
Title
Dose limited toxicity(DLT) observation and the incidence of treatment-emergent adverse events(TEAE) which more than or equal to grade 3 in each dose level
Description
DLT is defined as the incidence of severe adverse events related to ThisCART19A more than 33% in each dose level.
Time Frame
28 days
Title
The incidence of all grade TEAEs and ≥3 grade TEAEs
Description
Incidence of treatment-emergent adverse events (TEAEs) and ≥3 grade TEAEs
Time Frame
Up to 2 years after ThisCART19A infusion
Secondary Outcome Measure Information:
Title
Objective response rate
Description
Objective response rate (ORR = CR + CRi) of ThisCART19A within 3 months after administration
Time Frame
At Month 1, 2, 3
Title
The change characteristics of chimeric antigen receptor(CAR)-T cell number and copy number in patients after infusion
Description
Track CAR-T cells expansion in patients after infusion by flow cytometry and qPCR
Time Frame
3 months
Title
Changes in cytokine level after ThisCART19A infusion.
Description
Calculate the change of cytokine level in peripheral blood by flow cytometry after ThisCART19A infusion. Cytokines include IL-1β、IL-2、IL-4、IL-6、IL-8、IL-10、IL-12、IL-17、TNF-α、IFN-γ、TGF-β.
Time Frame
3 months
Title
Changes in immune effect cells count after ThisCART19A infusion.
Description
Calculate the change of immune effect cells count in peripheral blood by flow cytometry after ThisCART19A infusion. Immune effect cells include T cell, B cell, NK cell.
Time Frame
3 months
Title
MRD response rate
Description
Percentage of participants with minimal residual disease (MRD) response in patients with CR (complete response) and CRi (CR with incomplete blood count recovery) ; MRD Response is defined as leukemic cells in bone marrow <0.01% by flow cytometry (sensitivity at least 0.001%)
Time Frame
24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All subjects or legal representatives must sign a voluntary letter of consent approved by the IRB in person prior to the commencement of any screening procedure; Patients diagnosed with B-ALL according to the Chinese Guidelines for the Diagnosis and Treatment of Adult Acute Lymphoblastic Leukemia (2021 edition); There is no gender limitation, age 18-65 (upper limit not included); Consistent with the diagnosis of recurrent refractory B-ALL. Recurrence: was defined as the recurrence of lymphoblasts(≥5%) in peripheral blood or bone marrow or extramedullary diseasefor patients who had acquired CR ; Refractory :was defined as failure to CR or CRi at the end of induction therapy (generally referred to 4-week regimen or Hyper-CVAD regimen);Patients with Ph+ R/R ALL who failed after 2-line TKI treatment, were intolerant to TKI treatment or were not suitable for TKI treatment; The following factors can coexist: A) Failure to prepare autologous CAR-T (definition: too few autologous lymphocytes [200/ML] or cannot meet the release standard); B) Experienced treatment with auto car-T/berintoomumab/ CD22 antibody conjugation drugs; C) ≥100 days after hematopoietic stem cell transplantation; D) high-risk patients (High risk was defined as a high white blood cell count ≥30×109/L at diagnosis or with poor cytogenetic prognosis); Hypodiploid (<44 chromosomes); KMT2A rearrangement: t (4;11) or otherwise; t (v;q32)/IgH; t (9;22) (q34;q11.2) or BCR-ABL1; Complex karyotype (≥5 chromosomal abnormalities); BCR-ABL1-like (Ph-like) ALL; JAK-STAT (CRLF2r, EPORr, JAK1/2/3r, TYK2r, mutations of SH2B3, IL7r, Jak1/2/3 ); ABL class( rearrangement of ABL1, ABL2, PDGFRA, PDGFRB, FGFR); Other (NTRKr, FLT3r, LYNr, PTK2Br); Intrachromosomal amplification of chromosome 21 (IAMP21-ALL); t (17;19) : TCF3-HLF fusion ; Alterations of IKZF1; E) Extramedullary lesions. The expected survival time is ≥12 weeks; ECOG score 0-1; Had good organic function during screening CD19 was still expressed in leukemia cells in bone marrow, peripheral blood or biopsy tissue by flow cytometry within one month prior to informed consent (after the last treatment). Exclusion Criteria: Allergic to preconditioning measures. Patients with other malignancies other than B-cell malignancies within 5 years prior to screening. Patients with cured skin squamous carcinoma,basal carcinoma, non-primary invasive bladder cancer, localized low-risk prostate cancer, in situ cervical/breast cancer can be recruited. Uncontrollable bacterial, fungal and viral infection during screening. Patients had pulmonary embolism within 3 months prior to enrollment. Had intolerant severe cardiovascular and cerebrovascular diseases and hereditary diseases prior to enrollment. Imaging confirmed the presence of central nervous system involvement (both primary and secondary) and obvious symptoms at the time of screening. Active HBV or HCV or HIV or Syphilis infection. HBV-DNA < 2000 IU/mL can be enrolled, but should admitted to use anti-virus drugs such as entecavir, tenufovir, etc, and supervisory the relative indication during the treatment. Combined systemic steroid use (e.g., prednisone ≥20mg) within 3 days prior to screening. Or systemic diseases that require long-term use of immunization Inhibitor. Vaccinated with influenza vaccine within 2 weeks prior to cleansing (SARS-COV19 can be included, inactivated, live/non-live adjuvant vaccinations allowed to be included) . Patients who are receiving GvHD treatment; Patients without GvHD and who had stopped immunosuppressive drugs for at least 1 month were eligible for inclusion. Women who are in pregnant or lactating, and female subjects or partners who plan to be pregnant within 1 year after cell infusion. Male subjects who plan pregnancy within 1 year after infusion. Any ineligibility conditions considered by the investigator that may increase the risk of the subject or interfere with the results of the study;
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mingming Zhang, Doctor
Phone
13656674208
Email
mingmingzhang@zju.edu.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
He Huang, Doctor
Organizational Affiliation
The first hospital affiliated Zhejiang University
Official's Role
Principal Investigator
Facility Information:
Facility Name
The First Hospital of Zhejiang Medical Colleage Zhejiang University
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310003
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
He Huang, PhD
Phone
86-13605714822
Email
hehuangyu@126.com
First Name & Middle Initial & Last Name & Degree
Mingming Zhang, PhD
Phone
86-13656674208
Email
mingmingzhang@zju.edu.cn
Facility Name
The first affiliated hospital of medical college of zhejiang university
City
Hangzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mingming Zhang, Doctor
Phone
13656674208
Email
mingmingzhang@zju.edu.cn

12. IPD Sharing Statement

Learn more about this trial

Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL

We'll reach out to this number within 24 hrs